Futagami Masayuki, Yokoyama Yoshihito, Sato Tetsumi, Hirota Kazuyoshi, Shimada Muneaki, Miyagi Etsuko, Suzuki Nao, Fujimura Masaki
Department of Obstetrics and Gynecology and 2Department of Anesthesiology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, Aomori 036-8562, Japan. Email:
Asian Pac J Cancer Prev. 2016 Oct 1;17(10):4637-4642. doi: 10.22034/apjcp.2016.17.10.4637.
Purpose: To evaluate palliative care for patients with gynecologic cancer in Japan. Materials and Method: A questionnaire asking facility characteristics, systems to coordinate palliative care, current status of end-of-life care, provision of symptom relief, palliative radiation therapy and chemotherapy, and cases of death from gynecological cancer, was mailed to facilities treating gynecologic cancer. Results: A total of 115 facilities (29.3% of the total) responded to the questionnaire. Of these, 33.0 (29.0%) had a palliative care ward. End-of-life care was managed by obstetricians and gynecologists in 72.0% of the facilities. The site where end-of-life care was provided was most often a ward in the department where the respondent worked. The waiting period for transfer to a hospice was 2 weeks or more in 52% of facilities. Before the start of primary treatment, pain control was managed by obstetrians and gynecologists in 98.0% of facilities. Palliative radiation therapy or chemotherapy was administered at 93.9% and 92.0% of facilities, respectively. Of the 115 facilities, 34.0 (29.6%) reported cases of death from gynecological cancer. There were 1,134 cases of death. The median time between the last cycle of chemotherapy and death was 85 days for all gynecological cancers. The proportion of patients receiving chemotherapy in the last 30 and 14 days of life were 17.4% and 7.1%, respectively. Conclusions: This large-scale survey showed characteristics of palliative care given to patients with gynecologic cancer in Japan. Assessment of death cases showed that the median time between the last cycle of chemotherapy and death was relatively short.
评估日本妇科癌症患者的姑息治疗情况。材料与方法:向治疗妇科癌症的机构邮寄一份问卷,询问机构特征、姑息治疗协调系统、临终关怀现状、症状缓解措施、姑息性放疗和化疗情况以及妇科癌症死亡病例。结果:共有115家机构(占总数的29.3%)回复了问卷。其中,33家(29.0%)设有姑息治疗病房。72.0%的机构由妇产科医生管理临终关怀。提供临终关怀最常见的地点是受访者工作科室的病房。52%的机构将患者转至临终关怀机构的等待期为2周或更长时间。在初始治疗开始前,98.0%的机构由妇产科医生管理疼痛控制。分别有93.9%和92.0%的机构进行了姑息性放疗或化疗。在115家机构中,34家(29.6%)报告了妇科癌症死亡病例。共有1134例死亡。所有妇科癌症患者化疗最后一个周期至死亡的中位时间为85天。在生命的最后30天和14天接受化疗的患者比例分别为17.4%和7.1%。结论:这项大规模调查显示了日本妇科癌症患者姑息治疗的特点。对死亡病例的评估表明,化疗最后一个周期至死亡的中位时间相对较短。